Elsevier — which provides scientific, technical and medical information products and services — is acquiring Amirsys.
Focused on visually oriented medical disciplines like radiology, pathology and anatomy, Amirsys’ global solutions give healthcare providers the expert information and clinical decision support (CDS) tools to make informed, expert and evidence-based diagnoses. The company also provides learning environments that help those training in these disciplines to sharpen their diagnostic skills and increase their knowledge.
“This acquisition bolsters Elsevier’s comprehensive set of point-of-decision solutions, providing our customers around the world with a greater ability to improve the quality of care and patient outcomes,” said Jay Katzen, President of Elsevier Clinical Solutions. “In addition, because radiology, pathology, anatomy and their associated content and data-rich images are foundational elements of other disciplines, we believe Amirsys will improve our ability to better inform diagnostic and treatment decisions across a broad scope of other specialties.”
Salt Lake City, Utah-based Amirsys will be integrated with the Elsevier Clinical Solutions suite that includes clinical workflow and decision support, clinical reference and patient engagement.Amirsys also created tools to develop and maintain current imaging content, and Elsevier expects to be able to adapt those tools to serve other visually rich specialties. Amirsys products include STATdx, RADPrimer, ImmunoQuery, AnatomyOne and Amirsys Imaging, Pathology, and Anatomy Reference Centers.
As part of the deal, Amirsys will be integrated with the Elsevier Clinical Solutions suite that includes clinical workflow and decision support, clinical reference and patient engagement, including ClinicalKey, CPM CarePoints, ExitCare, and InOrder by Elsevier. In addition, Amirsys’ new editions and titles, publishing group and world-renowned author teams will complement Elsevier’s own portfolio of high quality radiology and pathology titles.
Amirsys is headquartered in Salt Lake City, Utah. The acquisition is effective immediately and financial terms of the transaction are not being disclosed.